UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2327) 2327
vidarabine - analogs & derivatives (2041) 2041
science & technology (1850) 1850
life sciences & biomedicine (1837) 1837
vidarabine - administration & dosage (1648) 1648
male (1645) 1645
female (1576) 1576
middle aged (1398) 1398
hematology (1227) 1227
adult (1202) 1202
aged (1025) 1025
oncology (918) 918
antineoplastic combined chemotherapy protocols - therapeutic use (865) 865
vidarabine - therapeutic use (685) 685
treatment outcome (655) 655
fludarabine (641) 641
cyclophosphamide - administration & dosage (585) 585
leukemia, lymphocytic, chronic, b-cell - drug therapy (579) 579
transplantation (541) 541
transplantation conditioning - methods (465) 465
vidarabine - adverse effects (437) 437
adolescent (427) 427
immunology (385) 385
disease-free survival (354) 354
transplantation, homologous (348) 348
rituximab (344) 344
antineoplastic combined chemotherapy protocols - adverse effects (336) 336
antineoplastic combined chemotherapy protocols - administration & dosage (320) 320
remission induction (320) 320
abridged index medicus (303) 303
retrospective studies (282) 282
recurrence (280) 280
animals (274) 274
survival rate (274) 274
survival analysis (271) 271
cytarabine - administration & dosage (269) 269
stem cells (260) 260
child (257) 257
aged, 80 and over (255) 255
busulfan - administration & dosage (253) 253
care and treatment (251) 251
antineoplastic agents - therapeutic use (249) 249
hematopoietic stem cell transplantation (249) 249
hematopoietic stem cell transplantation - methods (242) 242
hematopoietic stem cells (242) 242
follow-up studies (239) 239
young adult (227) 227
antineoplastic agents - administration & dosage (224) 224
cancer (221) 221
antibodies, monoclonal - administration & dosage (220) 220
chronic lymphocytic leukemia (215) 215
graft vs host disease - prevention & control (214) 214
drug administration schedule (212) 212
prognosis (207) 207
hematology, oncology and palliative medicine (197) 197
biophysics (192) 192
health aspects (191) 191
research (190) 190
risk factors (189) 189
combined modality therapy (188) 188
cyclophosphamide (188) 188
vidarabine - pharmacology (188) 188
transplantation conditioning (185) 185
antineoplastic agents (180) 180
dosage and administration (174) 174
antimitotic agents (171) 171
chemotherapy (170) 170
child, preschool (169) 169
leukemia (165) 165
leukemia, lymphocytic, chronic, b-cell - pathology (161) 161
hematopoietic stem cell transplantation - adverse effects (160) 160
antibodies, monoclonal, murine-derived (159) 159
leukemia, myeloid, acute - drug therapy (159) 159
time factors (158) 158
melphalan - administration & dosage (156) 156
prospective studies (153) 153
mice (151) 151
alemtuzumab (147) 147
leukemia, lymphocytic, chronic, b-cell - mortality (146) 146
antibodies, monoclonal, murine-derived - administration & dosage (143) 143
medicine & public health (143) 143
mitoxantrone - administration & dosage (139) 139
immunosuppressive agents - administration & dosage (136) 136
immunosuppressive agents - therapeutic use (136) 136
dose-response relationship, drug (135) 135
drug therapy, combination (134) 134
hematologic neoplasms - therapy (134) 134
drug therapy (128) 128
antineoplastic agents - adverse effects (125) 125
graft survival (125) 125
whole-body irradiation (125) 125
antilymphocyte serum - administration & dosage (124) 124
bone marrow (122) 122
graft vs host disease - etiology (122) 122
granulocyte colony-stimulating factor - administration & dosage (121) 121
stem cell transplantation (119) 119
cyclophosphamide - adverse effects (118) 118
vidarabine phosphate - analogs & derivatives (115) 115
antibodies, monoclonal - therapeutic use (114) 114
myeloablative agonists - administration & dosage (113) 113
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2390) 2390
Japanese (43) 43
Chinese (35) 35
French (28) 28
Spanish (18) 18
German (17) 17
Russian (9) 9
Hungarian (7) 7
Polish (3) 3
Czech (2) 2
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2009 - 2017
Summary Background Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Cyclophosphamide - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Female | Leukocyte Count | Child | Idarubicin - therapeutic use | Mitoxantrone - therapeutic use | Dexamethasone - administration & dosage | Risk Assessment | Kaplan-Meier Estimate | Mercaptopurine - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | United Kingdom | Vidarabine - analogs & derivatives | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Vidarabine - administration & dosage | Complications and side effects | Dosage and administration | Acute lymphocytic leukemia | Drug therapy | Patient outcomes | Mitoxantrone hydrochloride | Studies | Design | Medical research | Chemotherapy | Databases | Cytogenetics | Cancer therapies | Cancer | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 01/2019, Volume 20, Issue 1, pp. 31 - 42
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1164 - 1174
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2008, Volume 14, Issue 6, pp. 641 - 650
Abstract We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft rejection and graft-versus-host disease... 
Hematology, Oncology and Palliative Medicine | Bone marrow transplantation | Cyclophosphamide | Histocompatibility antigens | Conditioning regimens | Lymphoma | Leukemia | Transplantation | Immunology | Life Sciences & Biomedicine | Hematology | Science & Technology | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Recombinant Proteins | Bone Marrow Transplantation - methods | Cyclophosphamide - therapeutic use | Filgrastim | Transplantation, Homologous | Bone Marrow Transplantation - immunology | Adult | Female | Transplantation Conditioning - methods | Mycophenolic Acid - administration & dosage | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Drug Administration Schedule | Graft Survival | Postoperative Complications - epidemiology | Vidarabine - analogs & derivatives | Granulocyte Colony-Stimulating Factor - therapeutic use | Postoperative Care - methods | Blood Component Transfusion | Hematologic Neoplasms - surgery | Disease-Free Survival | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Hemoglobinuria, Paroxysmal - surgery | Cyclophosphamide - pharmacology | Graft vs Host Disease - prevention & control | Aged | Vidarabine - administration & dosage | Histocompatibility | Antimitotic agents | Evaluation | Mortality | Bone marrow | Dosage and administration | Antineoplastic agents | T cells | Cancer | Index Medicus
Journal Article
Journal Article